Low-dose exposure to inorganic mercury accelerates disease and mortality in acquired murine lupus. by Via, Charles S et al.
Exposures to mercury compounds are wide-
spread in the U.S. population and through-
out the world (Mahaffey and Mergler 1998;
National Research Council 2000). Although
public health concerns about mercury expo-
sures have generally focused on neurodevel-
opmental toxicity, mercury, particularly
inorganic mercury (iHg), has been extensively
studied in animal models for its immunotoxic
properties, which include both autoimmunity
and immunosuppression. The autoimmune
effects of iHg in susceptible rodent strains
include induction of speciﬁc autoantibodies,
polyclonal activation of T and B cells,
increased serum immunoglobulin G1
(IgG1) and IgE, cytokine dysregulation, and
an immune complex glomerulonephritis
(Bigazzi 1994; Griem and Gleichmann
1995; Mathieson 1992; Moszczynski 1997;
Pollard and Hultman 1997).
However, despite considerable study, no
associations have been found between mer-
cury exposure and autoimmune disease in
humans, even in highly exposed workers
(Moszczynski 1997; Sweet and Zelikoff 2001;
Vimercati et al. 2001). Experimental research
in animal models of Hg-induced autoimmu-
nity (HgIA) may suggest the reason for this.
In mice, genotype inﬂuences not only disease
susceptibility but also the specific autoanti-
bodies produced. One of the genes involved in
disease susceptibility is within the major histo-
compatibility complex (MHC) region. As a
result, H-2s mice (SJL, B10.S, A.SW) are
highly susceptible to HgIA induction to
include production of anti-nucleolar and anti-
ﬁbrillarin antibodies, whereas mice from other
MHC genotypes, for example, CBA (H-2k),
C57Bl/10 (H-2b), and DBA/2 (H-2d), are
resistant to disease induction (Hultman et al.
1992, 1993, 1996; Hultman and Enestrom
1987, 1992; Pietsch et al. 1992; Warfvinge et
al. 1995). Thus, the overt expression of HgIA
requires interactions with predisposing factors
such as genetic susceptibility; however, recent
studies indicate that Hg can also exacerbate
ongoing autoimmune disease. Studies in
spontaneously autoimmune-prone strains of
mice have reported greater autoimmune
responses to iHg in (NZB × NZW) F1 mice
compared with nonautoimmune SJL or
BALB/c mice (al-Balaghi et al. 1996) and also
reported that iHg treatment greatly increased
renal immune complex deposits in young
NZB × NZW F1 mice (Abedi-Valugerdi et al.
1997). Moreover, in the lupus-prone BXSB
mouse, Pollard et al. (2001) found that iHg
accelerated systemic autoimmunity, including
cellular and humoral features of disease.
Taken together, the above studies indicate
that iHg can interact with genetic factors to
either directly induce autoimmunity or acceler-
ate disease in autoimmune-prone animals. It is
not clear whether iHg can interact with non-
genetic factors to either increase susceptibility
to autoimmune disease or accelerate disease
course. In an animal model of acquired
autoimmune disease, experimental auto-
immune myocarditis, iHg pretreatment was
reported to exacerbate disease, including car-
diomyopathy and mortality, after infection
with coxsackie B virus (Ilback et al. 1996;
South et al. 2001); however, the doses used
were relatively high and by themselves caused
mortality (South et al. 2001).
The present study directly addresses
whether iHg preexposure can alter the subse-
quent course of autoimmunity induced by
nongenetic mechanisms. To this end, we used a
murine model of acquired autoimmunity, the
parent-into-F1 model of chronic graft-versus-
host disease (GVHD) in which a lupus-like dis-
ease is induced in otherwise normal mice that
are genetically resistant to the induction of
HgIA, for example, DBA/2 and B6D2F1 mice
(Via and Shearer 1988a). Moreover, we pur-
posely used very low doses of mercury (20 or
200 µg/kg every other day for 15 days) com-
pared with the range commonly used in studies
of Hg immunotoxicity (500–2,000 µg/kg for as
long as 3 months) in order to avoid potential
confounding by lethality or nonimmunologic
toxicity due to iHg. Our results indicate that a
brief, low-level exposure to iHg before the
induction of autoimmunity can significantly
worsen the subsequent course of disease.
Materials and Methods
Mice. We purchased 6- to 8-week-old female
B6D2F1 (BDF1) and DBA/2 mice from the
Jackson Laboratory (Bar Harbor, ME). All
studies were conducted under protocols
approved by the Institutional Animal Care
and Use Committee of the University of
Maryland, Baltimore.
iHg (HgCl2) administration. DBA/2
donor and BDF1 host mice were randomly
assigned to pretreatment groups, weighed, and
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Inorganic mercury (iHg) is known to induce autoimmune disease in susceptible rodent strains.
Additionally, in inbred strains of mice prone to autoimmune disease, iHg can accelerate and exac-
erbate disease manifestations. Despite these well-known links between iHg and autoimmunity in
animal models, no association between iHg alone and autoimmune disease in humans has been
documented. However, it is possible that low-level iHg exposure can interact with disease triggers
to enhance disease expression or susceptibility. To address whether exposure to iHg can alter the
course of subsequent acquired autoimmune disease, we used a murine model of acquired autoim-
munity, lupus-like chronic graft-versus-host disease (GVHD), in which autoimmunity is induced
using normal, nonautoimmune prone donor and F1 recipient mice resistant to Hg-induced
autoimmunity. Our results indicate that a 2-week exposure to low-dose iHg (20 or 200 µg/kg
every other day) to donor and host mice ending 1 week before GVHD induction can signiﬁcantly
worsen parameters of disease severity, resulting in premature mortality. iHg pretreatment clearly
worsened chronic lupus-like disease, rather than GVHD worsening iHg immunotoxicity. These
results are consistent with the hypothesis that low-level, nontoxic iHg preexposure may interact
with other risk factors, genetic or acquired, to promote subsequent autoimmune disease develop-
ment. Key words: autoimmunity, glomerulonephritis, graft-versus-host disease, lupus, mercury,
T cells. Environ Health Perspect 111:1273–1277 (2003). doi:10.1289/ehp.6064 available via
http://dx.doi.org/ [Online 1 April 2003]
Research Articlesadministered iHg dissolved in water and then
diluted to make doses of 20 or 200 µg/kg
(iHg20 or iHg200) in a total administered
volume of 0.1 mL/10 g animal. Controls
received equivolume injections of NaCl solu-
tion. NaCl or iHg was administered by subcu-
taneous injection every other day for 15 days
(or a total of eight doses) to both donors and
hosts. Animals were monitored daily for
weight loss, excessive urination, or other signs
of iHg toxicity. Five days after the last injec-
tion of iHg or NaCl, mice were assigned to
the following experimental groups: group A,
normal F1 mice; group B, sham (NaCl injec-
tion) + chronic GVHD (i.e., NaCl-treated
donor and host); group C, iHg20 + GVHD
(20 µg/kg iHg treatment of both donor and
host before GVHD induction); and group D,
iHg200 + GVHD (200 µg/kg iHg treatment
of both donor and host before GVHD induc-
tion). No mice treated with iHg only were
included in this preliminary study because
extensive experience with these treatments in
our laboratory and by others (Goering et al.
2000; Hultman et al. 1993; Silbergeld et al.
2000) has demonstrated that iHg, at these
doses, does not induce nephropathy, weight
loss, or mortality or affect other parameters
measured in this study in these mouse strains.
Induction of GVHD. Single-cell suspen-
sions of splenocytes were prepared from
DBA/2 females in phosphate-buffered saline,
filtered through sterile nylon mesh screen,
and diluted to a concentration of 108 viable
cells/mL as determined by trypan blue exclu-
sion. F1 mice received 80 × 106 parental cells
by intravenous administration. This dose of
parental donor cells is slightly above the
threshold for consistent induction of chronic
GVHD (~60–70 × 106 DBA/2 donor cells)
and has been reliably used by us to induce a
mild lupus-like disease (Rus et al. 1995;
Shustov et al. 2000; Via and Shearer 1988a).
Control mice consisted of age- and sex-
matched uninjected mice receiving no iHg
pretreatment.
Observational studies. A single cohort of
ﬁve mice/group was monitored for long-term
mortality and monthly proteinuria and serum
anti–single-stranded DNA (ssDNA) antibody
levels as described below. Animals were
inspected at least every other day. Date of
death was recorded, and dead animals were
promptly removed from the cages. Mice were
euthanized by CO2 inhalation when they
became moribund. Survival data were plotted
by the Kaplan-Meier method and analyzed by
the log-rank test.
Urine protein measurement. Proteinuria
was assessed semiquantitatively using urine
dip sticks (Albustix; Bayer Diagnostics,
Basingstoke, UK).
Flow cytometry studies. Splenocytes were
ﬁrst incubated with anti-murine FcγR mono-
clonal antibody (mAb) 2.4G2 (Unkeless 1979)
for 15–20 min and then stained with saturat-
ing concentration of fluorescein isothio-
cyanate-conjugated, phycoerythrin-conjugated,
or biotin-conjugated monoclonal antibody.
Fluorochrome conjugated anti-CD4, anti-
CD8, anti-B220, and anti-H2Kb were pur-
chased from Pharmingen (San Diego, CA).
Three-color flow cytometry was performed
using a FACScan flow cytometer (Becton-
Dickinson Immunocytometry Division, San
Jose, CA). Lymphocytes were gated based on
forward and side scatter, and analysis was per-
formed on 10,000 gated cells. Donor CD4+
and CD8+ T cells were identiﬁed as cells stain-
ing positive for the respective T-cell marker
and negatively for MHC class I of the non-
donor parent.
Serologic assays. Serum was tested by
enzyme-linked immunosorbent assay for the
presence of anti-ssDNA IgG antibodies as
previously described (Via et al. 2001). Optical
density was determined at 405 nm. Sera from
MRL/lpr mice were assayed as a standard and
arbitrary units calculated using a value of
1,000 units/mL for pooled undiluted
MRL/lpr sera. Immunofluorescent anti-
nuclear antibody (ANA) patterns were deter-
mined on Hep-2 cells using a commercial kit
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Figure 1. Pretreatment with iHg accelerates mortality
in chronic GVHD mice (n = 5 for each treatment
group). See “Materials and Methods” for details.
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Figure 2. Pretreatment with iHg accelerates the
appearance of proteinuria in chronic GVHD mice.
Proteinuria was tested at the times indicated, as
described in “Materials and Methods.”
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Figure 3. Pretreatment with iHg results in more severe glomerulonephritis in chronic GVHD mice. Mice
were sacriﬁced 127 days after GVHD induction, and kidneys were stained as described in “Materials and
Methods.” Representative histopathologic sections are shown for (A) untreated F1, (B) GVHD, (C) iHg20 +
GVHD, and (D) iHg200 + GVHD. Magniﬁcation: 400×. (The Binding Site, San Diego, CA) according
to the manufacturer’s instructions.
Assessment of glomerulonephritis. For
histopathology studies, renal tissue was ﬁxed
in 10% phosphate-buffered formalin, embed-
ded in paraffin, and stained routinely with
hematoxylin and eosin. All slides were scored
blindly by a renal pathologist (J.P.). The fol-
lowing glomerular features were graded:
mesangial hypercellularity, neutrophilic exu-
date, membrane thickness, crescents, and
glomerular cell apoptosis. For this purpose 15
ﬁelds were counted for each mouse and aver-
aged, and the average score ± SEM was calcu-
lated for each experimental group. In
addition, a glomerular activity score was cal-
culated based on measurement of glomerular
cellularity (composed of mesangial cells plus
neutrophilic exudates as well as crescents).
Tubulointerstitial features (perivascular inﬁl-
trates and tubular epithelial cell injury) were
graded semiquantitatively using the following
scale: 0 = normal/negative; 1+ = mild; 2+ =
moderate; 3+ = severe. A cumulative glomeru-
lar and tubular/interstitial severity index was
calculated for each individual mouse based on
scoring of 15 microscopic ﬁelds per mouse as
described (Shustov et al. 2000).
Statistical analysis. Data were examined for
normality and equal variance (Kolmogorov-
Smirnov). If satisfactory, groups were com-
pared by a two-tailed Student’s t-test; if not,
they were compared by the Mann-Whitney
rank sum test. For studies of scalar data
(histopathology scores and proteinuria col-
orimetry), the nonparametric data were com-
pared by the Mann-Whitney rank sum test.
Results
iHg pretreatment accelerates mortality in
chronic GVHD mice. As shown in Figure 1,
pretreatment with either low-dose or high-dose
iHg was associated with premature mortality
after GVHD induction. Deaths were not
observed within the time frame of this experi-
ment in either normal F1 mice or sham-
treated (NaCl, no iHg) chronic GVHD mice.
Although only the low-iHg group (iHg20 +
GVHD) had a statistically signiﬁcant increase
in mortality compared with normal F1 or
NaCl + GVHD controls (p = 0.0128), there
was no statistical difference between the high-
and low-dose iHg groups. It is likely that the
increased mortality in the high-dose iHg group
(iHg200 + GVHD) did not reach statistical
signiﬁcance due to the relatively small sample
size and the decision to terminate the experi-
ment at 4 months because of the morbidity in
surviving Hg + GVHD animals at that point.
iHg pretreatment accelerates lupus-like
renal disease in chronic GVHD mice. Lupus-
like renal disease in chronic GVHD mice is
mediated by glomerular deposition of immune
complexes, resulting in glomerulonephritis and
proteinuria (Bruijn et al. 1989; Shustov et al.
2000; van Elven et al. 1981). As shown in
Figure 2, iHg20 + GVHD mice exhibited ele-
vated proteinuria scores (> 1) at an earlier time
than did GVHD mice, and by 3 months 100%
of iHg20 + GVHD mice exhibited abnormal
proteinuria. Only a transient proteinuria was
observed in the control mice. No proteinuria
has been reported in earlier studies of iHg-
treated DBA/2 or C57Bl/6 mice (Goering et al.
2000; Hultman et al. 1993; Silbergeld et al.
2000). These results suggest that lupus-like
renal disease in GVHD mice is accelerated and
exacerbated by prior iHg treatment.
To fully deﬁne the extent of renal disease,
blinded glomerular scoring by light micro-
scopic analysis of the kidneys from all surviving
mice was performed by a renal pathologist at
12 weeks. Glomerulonephritis was observed
in both NaCl + GVHD and iHg + GVHD
mice as evidenced by glomerular enlarge-
ment, increased glomerular lobularity,
mesangial hypercellularity, and membrane
thickening, compared with control F1 mice
(Figure 3A–D). These changes are similar to
previous reports of glomerulonephritis in
chronic GVHD mice (Shustov et al. 2000);
however, glomerular disease was signiﬁcantly
more severe in iHg200 + GVHD mice, com-
pared with either untreated F1 mice (p <
0.0001) or NaCl + GVHD mice (p < 0.0001)
(mean glomerular scores: normal F1 = 2 9.6 ±
0.7, n = 5; NaCl + GVHD = 33.3 ± 1.2, n = 5;
iHg200 + GVHD = 53.62 ± 1.5, n = 3). The
glomerular score of the single survivor from the
iHg20 + GVHD group was 27.5.
Further analysis of the renal histopatho-
logic features demonstrated that GVHD alone
induces a tubular disease, which is not seen in
control F1 mice (mean tubular scores: normal
F1 = 0 vs. NaCl + GVHD = 6.2; p = 0.008).
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Figure 4. Effect of pretreatment with iHg on serum
anti-ssDNA antibodies in chronic GVHD mice. Mice
were bled at monthly intervals and anti-ssDNA
antibodies were determined as described in
“Materials and Methods.” Results are shown as
the mean ± SE for each group; n = 5 for all groups
except the following: n = 4 for iHg20 + GVHD at 3
months and n = 3 for iHg20 + GVHD and iHg200 +
GVHD at 4 months.
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Figure 5. Pretreatment with iHg does not alter the pattern of ANA in chronic GVHD mice. Representative
ANA patterns are shown for (A) untreated F1, (B) NaCl + GVHD, (C) iHg20 + GVHD, and (D) iHg200 + GVHD.
Mice were bled 4 months after GVHD induction, and the ANA pattern was determined as described in
“Materials and Methods” at a serum dilution of 1:80. Magniﬁcation: 400×. Exposure to iHg did not increase these
histopathologic ﬁndings; that is, there was no
significant difference in tubular damage in
iHg200 + GVHD mice (mean tubular score =
5.3, not significant) compared with NaCl +
GVHD mice. Taken together, these data sup-
port the conclusion that the doses of iHg used
in these studies do not induce an Hg-like renal
disease (tubular disease), but instead, iHg
accelerates ongoing lupus-like renal disease in
chronic GVHD mice
iHg pretreatment affects anti-ssDNA anti-
body production in chronic GVHD. We also
found interactions between iHg and GVHD
in molecular markers of autoimmunity. Serum
anti-ssDNA autoantibodies are an early and
reliable marker of B-cell hyperactivity and
autoimmunity in chronic GVHD and have
been shown to be quantitatively related to the
degree of T-cell–driven B-cell hyperactivity.
That is, the serum levels of anti-ssDNA in the
ﬁrst 2–4 weeks after parental cell transfer are
linearly related to the number of donor
splenocytes injected up to a dose of 108 cells
(Via and Shearer 1988b).
As shown in Figure 4, levels of anti-ssDNA
antibodies did not differ among the three
GVHD groups (NaCl, iHg20, or iHg200)
during the ﬁrst 8 weeks of disease. Thus, initial
B-cell activation and autoantibody production
in response to equivalent numbers of donor
T cells are not altered by iHg pretreatment.
However, by month 3, the iHg200 + GVHD
mice exhibited a significant increase in anti-
ssDNA autoantibodies compared with either
the NaCl + GVHD or iHg20 + GVHD mice.
These results suggest that lupus-like disease
undergoes an acceleration due to iHg expo-
sure between months 2 and 3 in iHg200 +
GVHD mice.
iHg pretreatment does not induce auto-
antibodies characteristic of iHg-associated
autoimmunity. The interactions between iHg
and GVHD do not appear to relate to an exac-
erbation of HgIA. That is, iHg is well known to
induce the production anti-nucleolar anti-
bodies, including anti-ﬁbrillarin, and a nucleo-
lar ANA pattern (Mirtcheva et al. 1989;
Monestier et al. 1994), which have been related
to the presence of antibodies to fibrillarin
(Pollard et al. 1997). In contrast, chronic lupus-
like GVHD is associated with a homogeneous
ANA pattern of fluorescence (Figure 5B).
Importantly, as shown in Figure 5C and D,
iHg + GVHD mice (both high and low dose)
exhibit only homogeneous ANA patterns at 4
months after treatment. All mice in the cohort
were tested, and a nucleolar ANA pattern was
not observed. All GVHD mice (with or with-
out iHg) exhibited homogeneous ANA pat-
terns, consistent with the conclusion that iHg
did not convert chronic GVHD to HgIA. In
the representative examples shown in Figure
5A–D, at a serum dilution of 1:80, the intensity
of ANA staining was greater for GVHD mice
that received iHg pretreatment (~3+ for
iHg200 + GVHD mice and 2+ for iHg20 +
GVHD mice, vs. 1+ for control GVHD mice
and negative for uninjected F1 mice).
The two iHg pretreatment doses may have
different effects on autoimmunity. Flow cyto-
metric analysis of surviving mice performed at
12 weeks indicates that typical features of
chronic GVHD (increased total spleen cell
numbers, host B-cell expansion, and donor
CD4+ T-cell engraftment in the absence of
donor CD8+ T-cell engraftment) were present
both in iHg200 + GVHD mice and in NaCl +
GVHD mice (Table 1). Total spleen cell
counts and host B-cell numbers were greater in
Hg200 + GVHD mice compared with NaCl +
GVHD mice; however, the differences were
statistically significant only for host B-cell
numbers. These results are consistent with the
data, discussed above, indicating that iHg at
200 µg/g exacerbates autoimmune manifesta-
tions and B-cell hyperactivity in GVHD mice.
Of note, the one surviving iHg20 + GVHD
mouse exhibited a marked increase in engraft-
ment of donor CD8+ T cells, which is not a
characteristic of chronic GVHD but is highly
characteristic of acute GVHD, suggesting that
the two different iHg doses may affect GVHD
differently. Further studies will be required to
determine whether these ﬁndings are represen-
tative of iHg20 + GVHD mice.
Discussion
It is well recognized that iHg exposure can
induce an autoimmune renal disease in geneti-
cally susceptible murine strains (Hultman et al.
1992, 1993, 1996; Hultman and Enestrom
1987, 1992; Pietsch et al. 1992; Warfvinge et
al. 1995) and that iHg exposure can exacerbate
disease in animal models of spontaneously
developing autoimmunity (Abedi-Valugerdi et
al. 1997; al-Balaghi et al. 1996; Pollard et al.
1999, 2001). Our study is the ﬁrst to use nor-
mal, genetically nonsusceptible mice (DBA/2
and B6D2F1) to examine the role of low-dose
iHg preexposure on the subsequent course of
acquired autoimmune disease. In the parent-
into-F1 model of lupus-like chronic GVHD,
the transfer of parental (donor) CD4+ T cells
into a nonirradiated F1 mouse (host) results in
donor T-cell recognition of host allogeneic
MHC II molecules, polyclonal host B-cell acti-
vation, autoantibody production (e.g., anti-
ssDNA antibodies), and immune complex
formation and deposition in renal glomeruli.
Mortality in this model is due to immune
complex glomerulonephritis (Bruijn et al.
1989; Shustov et al. 2000; van Elven et al.
1981). Of note, the severity of disease is
directly related to the number of donor cells
transferred (Van Rappard-Van Der Veen et al.
1983; Via and Shearer 1988b). In the present
study, we have used a relatively low donor cell
inoculum (8 × 107), which is just above the
threshold of disease induction. As a result,
autoimmune features such as serum anti-
ssDNA levels and histologic evidence of
glomerulonephritis were mild in GVHD mice
in the absence of iHg pretreatment, and there
was no mortality in this group at 4 months
after GVHD induction. This treatment
allowed us to observe inhibition or acceleration
of disease by iHg. We found that iHg pretreat-
ment signiﬁcantly worsened lupus-like disease,
as evidenced by earlier onset of proteinuria,
more severe histologic features of lupus-like
glomerulonephritis, and premature mortality.
It is important to note that these results were
induced using doses of iHg and a duration of
treatment that are substantially lower than
those used by most other studies of iHg
immunotoxicity. Pollard et al. (2001) reported
that low-dose iHg exposure could accelerate
disease in autoimmune prone BXSB mice. In
addition, in our experiments there was a 5-day
period between the last dose of iHg and donor
cell transfer, implying that iHg does not need
to be present during the induction of auto-
immune disease to enhance disease expression.
These results, taken together, indicate that
mercury has very potent interactive effects
with autoimmunity at doses considerably
lower than those required to induce autoim-
munity in susceptible mouse strains that do
not develop disease in the absence of iHg.
Several lines of evidence indicate that iHg
pretreatment in these experiments did not
directly result in Hg-induced autoimmune
disease but rather exacerbated the lupus-like
chronic manifestations of GVHD. First, the
mouse strains used (B6D2F1, DBA/2) are not
known to be susceptible to iHg-induced
immunotoxicity, and second, the doses of iHg
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Table 1. Pretreatment with high-dose iHg increases host B-cell numbers but does not alter splenic donor
T-cell chimerism in chronic GVHD mice.
Donor T cells Host
Group Spleen cells CD4+ CD8+ B cells
Untreated F1 (n = 5) 86 ± 1.6 ND ND 53.0 ± 1.3
NaCl + GVHD (n = 5) 118 ± 8.8 1.47 ± 0.3 0.25 ± 0.5 75.5 ± 6.7
iHg20 + GVHD (n = 1) 51.0 0.55 2.4  22.5
iHg200 + GVHD (n = 3) 140 ± 6.7  1.48 ± 0.4  0.47 ± 0.2 97.5 ± 4.8*
ND, not detectable over background (< 0.2 × 106 cells). Splenocytes were analyzed by ﬂow cytometry at 127 days post-
parental cell transfer as described in “Materials and Methods.” Values are shown as group mean ± SE × 10–6.
*p < 0.05, iHg200 + GVHD vs. NaCl + GVHD.used are well below exposures associated with
overt signs of autoimmunity, such as nephro-
pathy, renal histopathology, or death (Hultman
et al. 1993; Hultman and Hansson-Georgiadis
1999; Hultman and Nielsen 2001). Neither
the renal histology nor the immunologic mea-
surements were consistent with evidence of
iHg-related pathology. Moreover, HgIA is
associated with a nucleolar ANA pattern
(Monestier et al. 1994; Pollard et al. 1997). No
iHg-treated GVHD mice exhibited a nucleolar
ANA pattern. Instead, all mice showed a homo-
geneous ANA pattern characteristic of GVHD,
and iHg treatment increased the intensity of
ANA fluorescence compared with GVHD
mice, implying disease exacerbation.
These findings are consistent with the
findings by Pollard et al. (2001) in sponta-
neous models of lupus, in which Hg exposure
exacerbated underlying autoimmune disease,
rather than the genotype exacerbating Hg tox-
icity. Our results extend these observations by
demonstrating that iHg can also accelerate and
exacerbate acquired autoimmune disease even
when exposure precedes disease. Studies are in
progress to determine the maximal time that
iHg exposure can precede disease induction
and still exert a synergistic effect on disease
expression.
Of note, the effects of iHg pretreatment on
GVHD appeared to vary with the doses used,
although these observations are limited by the
reduction in survivors available for analysis.
Both doses of iHg (20 or 200 µg/kg × 8 doses)
accelerated mortality; however, in iHg200 +
GVHD mice, other measurements indicated
an acceleration or exacerbation of disease, for
example, increased anti-ssDNA titers at 3
months and increased intensity of ANA stain-
ing. In contrast, in the one surviving iHg20 +
GVHD mouse, the marked increase in engraft-
ment of donor CD8+ T cells suggests that this
dose of iHg may have converted chronic
GVHD to acute GVHD. We have previously
observed that in the GVHD model used here,
chronic GVHD can be converted to acute
GVHD by the administration of agents that
promote TH1 cytokine responses, for example,
administration of recombinant interleukin 12
(Via et al. 1994), or by highly selective costim-
ulatory blockade in which the down-regulatory
signal delivered by CTLA4 through its prefer-
ential ligand CD80 is inhibited (Lang et al.
2002). Because both CD80 and CD86 appear
to be required for HgIA (Bagenstose et al.
2002), we are currently investigating whether
low-dose iHg preexposure promotes TH1
cytokine production and/or interferes with
CTLA4-CD80 expression or ligand binding.
In conclusion, it is becoming increasingly
accepted that the development of autoimmune
disease in humans involves a combination of
factors, which include the appropriate genetic
predisposition and encounter(s) with acquired
risk factors in the environment, including
infections and immunotoxic agents. Our
results support the hypothesis that low-level
environmental exposure to Hg is one potential
factor in the development of autoimmune dis-
ease. Speciﬁcally, low-level iHg exposure likely
does not induce disease by itself; however, it
may lower the threshold for disease develop-
ment in susceptible individuals who later
encounter the appropriate infectious or toxic
triggers of disease.
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